Open Access<p>Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma</p>
Author(s) -
Yu Hei,
BingHong Teng,
Ziqian Zeng,
SiQi Zhang,
Qian Li,
Jijia Pan,
Zhuojing Luo,
Chunyang Xiong,
Shicheng Wei
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s225807
Subject(s) - in vivo , melanoma , immunotherapy , tumor microenvironment , cancer research , immune system , tumor hypoxia , hypoxia (environmental) , monoclonal antibody , in vitro , pharmacology , chemistry , medicine , antibody , immunology , biology , biochemistry , radiation therapy , microbiology and biotechnology , organic chemistry , oxygen
Immune checkpoint blockades (ICBs) are a promising treatment for cancers such as melanoma by blocking important inhibitory pathways that enable tumor cells to evade immune attack. Programmed death ligand 1 monoclonal antibodies (aPDL1s) can be used as an ICB to significantly enhance the effectiveness of tumor immunotherapy by blocking the PD-1/PD-L1 inhibitory pathway. However, the effectiveness of aPDL1s may be limited by low selectivity in vivo and immunosuppressed tumor microenvironment including hypoxia.